RMC No. 58-2022 publishes FDA corrections to VAT-exempt medicines, affecting hypertension and COVID-19 treatments. Businesses must update records and invoices to remain compliant.
Businesses and healthcare providers must immediately note changes to the VAT-exempt status of certain medicines. RMC No. 58-2022 publishes the FDA’s updates correcting names of specific medicines used for hypertension and COVID-19 treatment under RA No. 11534 (CREATE Act), directly impacting tax compliance and invoicing.
What Changed
The Department of Finance, through the Bureau of Internal Revenue, has formally endorsed the FDA’s March 10, 2022 letter updating the official List of VAT-Exempt Medicines. The primary change is the correction of the names of certain medicines prescribed for hypertension and COVID-19 treatment, ensuring proper alignment with current pharmaceutical listings.
Who Is Affected
All VAT-registered pharmacies, hospitals, clinics, and other healthcare providers selling medicines are affected. Pharmaceutical manufacturers and distributors must also adjust their invoicing systems and internal accounting records to reflect the corrected medicine names. CFOs, accountants, and in-house tax counsel must ensure that transactions for these medicines remain compliant with VAT exemption rules to avoid penalties.
Key Compliance Requirements
Businesses should immediately update their billing systems, POS software, and accounting records to match the corrected names in the updated VAT-exempt list. Any sale invoices issued for the affected medicines must reflect these changes to claim VAT exemption accurately. Companies must also maintain proper documentation evidencing that these medicines are indeed VAT-exempt under RA No. 11534.
Deadlines
The circular takes effect upon its issuance on April 27, 2022. Businesses should implement the necessary adjustments immediately to ensure compliance in ongoing and future transactions.
Penalties for Non-Compliance
Failure to correctly apply the VAT exemption to these medicines may result in assessments for unpaid VAT, penalties, and interest under the National Internal Revenue Code. Proper documentation and adherence to the updated list mitigate risk during tax audits or reviews.
Practical Steps for Businesses
1. Obtain the updated VAT-exempt list and verify the corrected medicine names for hypertension and COVID-19 treatment.
2. Update all internal accounting, invoicing, and inventory systems to reflect the corrected names.
3. Train staff responsible for billing and tax compliance on the updates.
4. Maintain records evidencing the sale of these VAT-exempt medicines for audit purposes.
5. Review contracts and supply agreements to ensure proper labeling and documentation for compliance.
Conclusion
RMC No. 58-2022 is a critical update for healthcare providers and businesses dealing with medicines under VAT exemption. Immediate attention ensures compliance and prevents potential tax disputes. Ablola, Saribong & Gueco stands ready to guide businesses through implementation and audit preparation for VAT-exempt transactions. Visit MakatiLawFirm.com for expert assistance on VAT compliance and regulatory updates.